Does the media prefer DGX or HSIC?

In the previous week, Quest Diagnostics had 10 more articles in the media than Henry Schein. MarketBeat recorded 15 mentions for Quest Diagnostics and 5 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 1.19 beat Henry Schein's score of 0.78 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MEDP or DGX?

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.48 $451.12M $17.06 34.44 Quest Diagnostics $11.04B 2.35 $992M $9.42 24.93

Is MEDP or DGX more profitable?

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Quest Diagnostics 9.18% 16.01% 7.27%

Does the media favor MEDP or DGX?

In the previous week, Quest Diagnostics had 5 more articles in the media than Medpace. MarketBeat recorded 15 mentions for Quest Diagnostics and 10 mentions for Medpace. Medpace's average media sentiment score of 1.63 beat Quest Diagnostics' score of 1.19 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Quest Diagnostics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMN or DGX?

In the previous week, Quest Diagnostics had 10 more articles in the media than AMN Healthcare Services. MarketBeat recorded 15 mentions for Quest Diagnostics and 5 mentions for AMN Healthcare Services. Quest Diagnostics' average media sentiment score of 1.19 beat AMN Healthcare Services' score of 0.92 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LH or DGX?

In the previous week, Labcorp had 6 more articles in the media than Quest Diagnostics. MarketBeat recorded 21 mentions for Labcorp and 15 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.19 beat Labcorp's score of 0.56 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 8 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DGX or CI?

In the previous week, Cigna Group had 5 more articles in the media than Quest Diagnostics. MarketBeat recorded 20 mentions for Cigna Group and 15 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.19 beat Cigna Group's score of 0.92 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cigna Group 11 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Quest Diagnostics (DGX) Competitors

$234.80 +3.66 (+1.59%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$233.54 -1.27 (-0.54%)

As of 09/11/2026 07:32 PM Eastern

Compare

DGX vs. HSIC, MEDP, AMN, LH, and CI

Should you buy Quest Diagnostics stock or one of its competitors? Quest Diagnostics's main competitors and comparable companies include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and Cigna Group (CI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Quest Diagnostics compare to Henry Schein?

Quest Diagnostics (NYSE:DGX) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Quest Diagnostics has a net margin of 9.18% compared to Henry Schein's net margin of 2.96%. Quest Diagnostics' return on equity of 16.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Henry Schein	2.96%	15.97%	5.56%

In the previous week, Quest Diagnostics had 10 more articles in the media than Henry Schein. MarketBeat recorded 15 mentions for Quest Diagnostics and 5 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 1.19 beat Henry Schein's score of 0.78 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Quest Diagnostics currently has a consensus price target of $236.31, suggesting a potential upside of 0.64%. Henry Schein has a consensus price target of $92.93, suggesting a potential upside of 5.18%. Given Henry Schein's higher probable upside, analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 0.9% of Henry Schein shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Quest Diagnostics has higher earnings, but lower revenue than Henry Schein. Quest Diagnostics is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.35	$992M	$9.42	24.93
Henry Schein	$13.18B	0.75	$398M	$3.43	25.76

Summary

Quest Diagnostics beats Henry Schein on 10 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Medpace (NASDAQ:MEDP) and Quest Diagnostics (NYSE:DGX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Quest Diagnostics	9.18%	16.01%	7.27%

In the previous week, Quest Diagnostics had 5 more articles in the media than Medpace. MarketBeat recorded 15 mentions for Quest Diagnostics and 10 mentions for Medpace. Medpace's average media sentiment score of 1.63 beat Quest Diagnostics' score of 1.19 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace presently has a consensus target price of $595.20, suggesting a potential upside of 1.31%. Quest Diagnostics has a consensus target price of $236.31, suggesting a potential upside of 0.64%. Given Medpace's higher probable upside, equities research analysts plainly believe Medpace is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

78.0% of Medpace shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.48	$451.12M	$17.06	34.44
Quest Diagnostics	$11.04B	2.35	$992M	$9.42	24.93

Summary

Medpace beats Quest Diagnostics on 10 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

AMN Healthcare Services has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

AMN Healthcare Services presently has a consensus price target of $36.00, indicating a potential upside of 8.02%. Quest Diagnostics has a consensus price target of $236.31, indicating a potential upside of 0.64%. Given AMN Healthcare Services' higher probable upside, analysts plainly believe AMN Healthcare Services is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

In the previous week, Quest Diagnostics had 10 more articles in the media than AMN Healthcare Services. MarketBeat recorded 15 mentions for Quest Diagnostics and 5 mentions for AMN Healthcare Services. Quest Diagnostics' average media sentiment score of 1.19 beat AMN Healthcare Services' score of 0.92 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.47	-$95.70M	$2.68	12.44
Quest Diagnostics	$11.04B	2.35	$992M	$9.42	24.93

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Quest Diagnostics has a net margin of 9.18% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	3.06%	19.92%	5.93%
Quest Diagnostics	9.18%	16.01%	7.27%

Summary

Quest Diagnostics beats AMN Healthcare Services on 13 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Labcorp (NYSE:LH) and Quest Diagnostics (NYSE:DGX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Labcorp had 6 more articles in the media than Quest Diagnostics. MarketBeat recorded 21 mentions for Labcorp and 15 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.19 beat Labcorp's score of 0.56 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	8 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a net margin of 9.18% compared to Labcorp's net margin of 6.99%. Labcorp's return on equity of 16.74% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
Quest Diagnostics	9.18%	16.01%	7.27%

Labcorp currently has a consensus target price of $336.36, suggesting a potential upside of 8.03%. Quest Diagnostics has a consensus target price of $236.31, suggesting a potential upside of 0.64%. Given Labcorp's stronger consensus rating and higher probable upside, equities research analysts clearly believe Labcorp is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

Quest Diagnostics has lower revenue, but higher earnings than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.81	$876.50M	$12.09	25.75
Quest Diagnostics	$11.04B	2.35	$992M	$9.42	24.93

Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. Labcorp pays out 23.8% of its earnings in the form of a dividend. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Labcorp has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 0.8% of Labcorp shares are owned by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Labcorp beats Quest Diagnostics on 12 of the 20 factors compared between the two stocks.

How does Quest Diagnostics compare to Cigna Group?

Quest Diagnostics (NYSE:DGX) and Cigna Group (NYSE:CI) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Cigna Group has higher revenue and earnings than Quest Diagnostics. Cigna Group is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.35	$992M	$9.42	24.93
Cigna Group	$274.90B	0.27	$5.96B	$24.17	11.61

In the previous week, Cigna Group had 5 more articles in the media than Quest Diagnostics. MarketBeat recorded 20 mentions for Cigna Group and 15 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.19 beat Cigna Group's score of 0.92 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cigna Group	11 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics presently has a consensus price target of $236.31, suggesting a potential upside of 0.64%. Cigna Group has a consensus price target of $337.10, suggesting a potential upside of 20.17%. Given Cigna Group's stronger consensus rating and higher possible upside, analysts plainly believe Cigna Group is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Cigna Group	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65

Quest Diagnostics has a net margin of 9.18% compared to Cigna Group's net margin of 2.27%. Cigna Group's return on equity of 19.75% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Cigna Group	2.27%	19.75%	5.34%

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. Cigna Group pays an annual dividend of $6.24 per share and has a dividend yield of 2.2%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Cigna Group pays out 25.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years and Cigna Group has raised its dividend for 5 consecutive years. Cigna Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Quest Diagnostics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Cigna Group has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 87.0% of Cigna Group shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 0.6% of Cigna Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Quest Diagnostics and Cigna Group tied by winning 10 of the 20 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DGX vs. The Competition

Export

Metric	Quest Diagnostics	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$25.94B	$9.84B	$7.16B	$23.37B
Dividend Yield	1.46%	2.61%	2.57%	3.56%
P/E Ratio	24.93	33.53	274.94	28.72
Price / Sales	2.35	4.89	686.57	20.04
Price / Cash	15.49	125.15	76.65	34.17
Price / Book	3.62	5.29	10.33	4.74
Net Income	$992M	$313.25M	$3.50B	$1.07B
7 Day Performance	-0.82%	-1.26%	-3.32%	-2.00%
1 Month Performance	-0.68%	-1.53%	-0.53%	-3.20%
1 Year Performance	28.41%	58.44%	23.51%	10.51%

Quest Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DGX Quest Diagnostics	4.4194 of 5 stars	$234.80 +1.6%	$236.31 +0.6%	+28.4%	$25.94B	$11.04B	24.93	57,000	Positive News Analyst Forecast Analyst Revision
HSIC Henry Schein	2.0988 of 5 stars	$89.81 flat	$92.93 +3.5%	+28.0%	$10.01B	$13.18B	26.18	25,000
MEDP Medpace	2.8118 of 5 stars	$591.29 flat	$595.20 +0.7%	+19.7%	$16.50B	$2.53B	34.66	6,200	Positive News
AMN AMN Healthcare Services	1.9264 of 5 stars	$33.80 flat	$31.43 -7.0%	+82.9%	$1.31B	$2.73B	12.61	2,664	Analyst Forecast
LH Labcorp	4.1203 of 5 stars	$326.83 0.0%	$330.00 +1.0%	+12.0%	$26.51B	$13.95B	27.03	71,000	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DGX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and CI

How does Quest Diagnostics compare to Henry Schein?

Summary

How does Quest Diagnostics compare to Medpace?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Summary

How does Quest Diagnostics compare to Labcorp?

Summary

How does Quest Diagnostics compare to Cigna Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and CI

How does Quest Diagnostics compare to Henry Schein?

Is DGX or HSIC more profitable?

Does the media prefer DGX or HSIC?

Which has more risk and volatility, DGX or HSIC?

Do analysts rate DGX or HSIC?

Do institutionals & insiders hold more shares of DGX or HSIC?

Which has preferable valuation & earnings, DGX or HSIC?

Summary

How does Quest Diagnostics compare to Medpace?

Which has more volatility and risk, MEDP or DGX?

Is MEDP or DGX more profitable?

Does the media favor MEDP or DGX?

Do analysts prefer MEDP or DGX?

Do institutionals and insiders hold more shares of MEDP or DGX?

Which has higher earnings and valuation, MEDP or DGX?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Which has more risk and volatility, AMN or DGX?

Do analysts rate AMN or DGX?

Does the media favor AMN or DGX?

Which has preferable valuation & earnings, AMN or DGX?

Do insiders and institutionals believe in AMN or DGX?

Is AMN or DGX more profitable?

Summary

How does Quest Diagnostics compare to Labcorp?

Does the media refer more to LH or DGX?

Is LH or DGX more profitable?

Do analysts prefer LH or DGX?

Which has preferable valuation and earnings, LH or DGX?

Is LH or DGX a better dividend stock?

Which has more risk & volatility, LH or DGX?

Do insiders & institutionals believe in LH or DGX?

Summary

How does Quest Diagnostics compare to Cigna Group?

Which has higher earnings and valuation, DGX or CI?

Does the media refer more to DGX or CI?

Do analysts prefer DGX or CI?

Is DGX or CI more profitable?

Is DGX or CI a better dividend stock?

Which has more volatility & risk, DGX or CI?

Do institutionals and insiders hold more shares of DGX or CI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools